UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

 

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended JanuaryJuly 31, 2010

or

 

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to

Commission file number 0-5286

 

 

KEWAUNEE SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 38-0715562

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

2700 West Front Street

Statesville, North Carolina

 28677-2927
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (704) 873-7202

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this Chapter)chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ¨    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer¨Accelerated filer¨
Non-accelerated filer Accelerated filer ¨

Non-accelerated filer ¨

(Do  (Do not check if a smaller

reporting company)

  Smaller reporting companyx

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of March 2,September 7, 2010, the registrant had outstanding 2,572,7432,573,100 shares of Common Stock.

 

 

 


KEWAUNEE SCIENTIFIC CORPORATION

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JANUARYJULY 31, 2010

 

      Page Number

PART I. FINANCIAL INFORMATION

  

Item 1.1

  

Financial Statements

  
  

Consolidated Statements of Operations – Three and Nine months ended JanuaryJuly 31, 2010 and 2009

  1
  

Consolidated Balance Sheets – JanuaryJuly 31, 2010 and April 30, 20092010

  2
  

Consolidated Statements of Cash Flows – NineThree months ended JanuaryJuly 31, 2010 and 2009

  3
  

Notes to Consolidated Financial Statements

  4

Item 2.2

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

  6
  

Review by Independent Registered Public Accounting Firm

8
Report of Independent Registered Public Accounting Firm  9

Item 3

  

Report of Independent Registered Public Accounting FirmQuantitative and Qualitative Disclosures About Market Risk

  10

Item 3.

Quantitative and Qualitative Disclosures About Market Risk4

  11
Item 4.

Controls and Procedures

  1110

PART II. OTHER INFORMATION

  

Item 6.

Exhibits6

  12Exhibits11

SIGNATURE

  1312

 

i


Part 1. Financial Information

 

Item 1.Financial Statements

Kewaunee Scientific Corporation

Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

 

  Three months ended
January 31
 Nine months ended
January 31
   Three months ended
July  31,
 
  2010 2009 2010 2009   2010 2009 

Net sales

  $21,814   $26,023   $75,151   $79,150    $24,858   $26,249  

Costs of products sold

   17,129    21,089    58,492    62,846     19,859    20,485  
                    

Gross profit

   4,685    4,934    16,659    16,304     4,999    5,764  

Operating expenses

   3,663    3,440    11,605    10,884     3,901    3,966  
                    

Operating earnings

   1,022    1,494    5,054    5,420     1,098    1,798  

Other income (expense)

   —      3    —      (36

Interest expense

   (35  (49  (115  (231   (45  (41
                    

Earnings before income taxes

   987    1,448    4,939    5,153     1,053    1,757  

Income tax expense

   333    488    1,673    1,595     329    589  
                    

Net earnings

   654    960    3,266    3,558     724    1,168  

Less: net earnings attributable to the noncontrolling interest

   33    78    222    231     (67  (97
                    

Net earnings attributable to Kewaunee Scientific Corporation

  $621   $882   $3,044   $3,327    $657   $1,071  
                    

Net earnings per share attributable to Kewaunee Scientific Corporation stockholders

        

Basic

  $0.24   $0.35   $1.19   $1.30    $0.26   $0.42  

Diluted

  $0.24   $0.35   $1.18   $1.30    $0.25   $0.42  

Weighted average number of common shares outstanding (in thousands)

        

Basic

   2,569    2,556    2,562    2,554     2,573    2,556  

Diluted

   2,581    2,556    2,570    2,563     2,578    2,558  

See accompanying notes to consolidated financial statements.

Kewaunee Scientific Corporation

Consolidated Balance Sheets

(in thousands)

 

  January 31,
2010
 April 30,
2009
   July 31,
2010
 April 30,
2010
 
  (Unaudited)     (Unaudited)   

Assets

      

Current assets:

   

Current Assets:

   

Cash and cash equivalents

  $1,937   $3,559    $1,812   $1,722  

Restricted cash

   506    456     521    544  

Receivables, less allowance

   23,007    24,526     27,425    26,169  

Inventories

   7,924    7,839     8,226    8,350  

Deferred income taxes

   330    309     392    390  

Prepaid expenses and other current assets

   1,255    856     1,369    1,407  
              

Total current assets

   34,959    37,545  

Total Current Assets

   39,745    38,582  

Property, plant and equipment, at cost

   41,738    39,298     45,352    43,200  

Accumulated depreciation

   (29,129  (27,929   (29,947  (29,385
              

Net property, plant and equipment

   12,609    11,369  

Net Property, Plant and Equipment

   15,405    13,815  

Deferred income taxes

   351    351     690    663  

Other

   3,684    3,264     3,540    3,561  
              

Total other assets

   4,035    3,615  

Total Other Assets

   4,230    4,224  
              

Total Assets

  $51,603   $52,529    $59,380   $56,621  
              

Liabilities and Stockholders’ Equity

      

Current liabilities:

   

Current Liabilities:

   

Short-term borrowings

  $2,909   $5,720    $7,496   $4,872  

Current obligations under capital leases

   96    220     78    82  

Accounts payable

   6,082    8,812     9,046    9,540  

Employee compensation and amounts withheld

   1,521    1,709     1,514    1,358  

Deferred revenue

   708    1,298     714    586  

Other accrued expenses

   2,316    904     1,956    2,059  
              

Total current liabilities

   13,632    18,663  

Total Current Liabilities

   20,804    18,497  

Obligations under capital leases

   139    201     99    119  

Accrued employee benefit plan costs

   6,533    5,406     6,464    6,333  
             ��

Total Liabilities

   20,304    24,270     27,367    24,949  

Equity:

      

Common Stock

   6,550    6,550  

Common stock

   6,550    6,550  

Additional paid-in-capital

   765    614     890    855  

Retained earnings

   28,127    25,802     28,798    28,398  

Accumulated other comprehensive loss

   (5,298  (5,521   (5,025  (4,898

Common stock in treasury, at cost

   (470  (492   (473  (472
              

Total Kewaunee Scientific Corporation stockholders’ equity

   29,674    26,953  

Total Kewaunee Scientific Corporation Stockholders’ Equity

   30,740    30,433  

Noncontrolling interest

   1,625    1,306     1,273    1,239  
              

Total Equity

   31,299    28,259     32,013    31,672  
              

Total Liabilities and Stockholders’ Equity

  $51,603   $52,529  

Total Liabilities and Equity

  $59,380   $56,621  
              

See accompanying notes to consolidated financial statements.

Kewaunee Scientific Corporation

Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

 

  Nine months ended
January 31
   Three months ended
July  31,
 
  2010 2009   2010 2009 

Cash flows from operating activities:

      

Net earnings

  $3,044   $3,327    $724   $1,168  

Adjustments to reconcile net earnings to net cash provided by (used in) operating activities:

   

Adjustments to reconcile net earnings to net cash (used in) provided by operating activities:

   

Depreciation

   1,840    1,687     589    615  

Bad debt provision

   107    164     43    36  

Provision for deferred income tax expense

   (21  (10   (29  17  

Decrease in prepaid income taxes

   9    812     —      9  

Decrease (increase) in receivables

   1,412    (4,800

Increase in inventories

   (85  (694

Increase in prepaid pension cost

   —      (222

(Increase) decrease in receivables

   (1,299  616  

Decrease (increase) in inventories

   124    (1,509

(Decrease) increase in accounts payable and other accrued expenses

   (1,506  265     (441  651  

(Decrease) increase in deferred revenue

   (590  364  

Increase (decrease) in deferred revenue

   128    (339

Other, net

   817    (553   73    (18
              

Net cash provided by operating activities

   5,027    340  

Net cash (used in) provided by operating activities

   (88  1,246  

Cash flows from investing activities:

      

Capital expenditures

   (3,080  (1,156   (2,179  (2,011

(Increase) decrease in restricted cash

   (50  82  

Decrease (increase) in restricted cash

   23    (11
              

Net cash used in investing activities

   (3,130  (1,074   (2,156  (2,022

Cash flows from financing activities:

      

(Decrease) increase in short-term borrowings

   (2,811  1,264  

Dividends paid

   (257  (205

Increase in short-term borrowings

   2,624    509  

Payments on capital leases

   (186  (280   (24  (81

Dividends paid

   (719  (613

Dividends paid to minority interest in subsidiaries

   —      (498

Purchase of treasury stock

   (245  (198

Purchase of Treasury Stock

   (36  —    

Proceeds from exercise of stock options (including tax benefit)

   267    298     35    —    
              

Net cash used in financing activities

   (3,694  (27

Net cash provided by financing activities

   2,342    223  

Effect of exchange rate changes on cash

   175    (332   (8  38  
              

Decrease in cash and cash equivalents

   (1,622  (1,093

Increase (decrease) in cash and cash equivalents

   90    (515

Cash and cash equivalents, beginning of period

   3,559    3,784     1,722    3,559  
              

Cash and cash equivalents, end of period

  $1,937   $2,691    $1,812   $3,044  
              

See accompanying notes to consolidated financial statementsstatements.

Kewaunee Scientific Corporation

Notes to Consolidated Financial Statements

(unaudited)

A.Financial Information

The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the “Company” or “Kewaunee”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s 20092010 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

The preparation of the interim consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates. In preparing these interim consolidated financial statements, we have reviewed and considered for disclosure all significant events occurring through March 12, 2010, the date of financial statement issuance.

B.Inventories

Inventories consisted of the following (in thousands):

 

  January 31, 2010  April 30, 2009  July 31, 2010  April 30, 2010

Finished products

  $1,871  $1,756  $1,825  $2,199

Work in process

   1,521   1,461   1,374   1,237

Raw materials

   4,532   4,622   5,027   4,914
            
  $7,924  $7,839  $8,226  $8,350
            

For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim consolidated financial statements in the period in which they occur.

C.Comprehensive Income

A reconciliation of net earnings and total comprehensive income for the three and nine months ended JanuaryJuly 31, 2010 and 2009 is as follows (in thousands):

 

  Three months ended
January 31, 2010
 Three months ended
January 31, 2009
   Three months ended
July 31, 2010
 Three months ended
July 31, 2009

Net earnings

  $621   $882    $657   $1,071

Change in cumulative foreign currency translation adjustments

   39    82     (116  104

Change in fair value of cash flow hedge, net of tax

   (29  —       (11  —  
             

Total comprehensive income

  $631   $964    $530   $1,175
             
  Nine months ended
January 31, 2010
 Nine months ended
January 31, 2009
 

Net earnings

  $3,044   $3,327  

Change in cumulative foreign currency translation adjustments

   252    (642

Change in fair value of cash flow hedge, net of tax

   (29  —    
       

Total comprehensive income

  $3,267   $2,685  
       

Assets and liabilities for the Company’s foreign subsidiaries are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in stockholders’ equity.

D.Segment Information

The following table provides financial information by business segments for the three and nine months ended JanuaryJuly 31, 2010 and 2009 (in thousands):

 

  Domestic
Operations
  International
Operations
  Corporate Total  Domestic
Operations
  International
Operations
  Corporate Total

Three months ended January 31, 2010

       

Three months ended July 31, 2010

       

Revenues from external customers

  $19,081  $2,733  $—     $21,814  $20,948  $3,910  $—     $24,858

Intersegment revenues

   477   23   (500  —     663   644   (1,307  —  

Operating earnings (loss) before income taxes

   1,538   127   (678  987   1,585   228   (760  1,053

Three months ended January 31, 2009

       

Three months ended July 31, 2009

       

Revenues from external customers

  $22,498  $3,525   —     $26,023  $23,358  $2,891  $—     $26,249

Intersegment revenues

   347   234   (581  —     420   107   (527  —  

Operating earnings (loss) before income taxes

   1,769   302   (623  1,448   2,545   303   (1,091  1,757

Nine months ended January 31, 2010

       

Revenues from external customers

  $67,152  $7,999  $—     $75,151

Intersegment revenues

   1,169   441   (1,610  —  

Operating earnings (loss) before income taxes

   6,984   636   (2,681  4,939

Nine months ended January 31, 2009

       

Revenues from external customers

  $67,296  $11,854  $—     $79,150

Intersegment revenues

   1,984   259   (2,243  —  

Operating earnings (loss) before income taxes

   6,501   1,025   (2,373  5,153

E.Defined Benefit Pension Plans

The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees. These plans were amended as of April 30, 2005, no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. No contributions were paid to the plans during the ninethree months ended JanuaryJuly 31, 2010 and 2009. The Company calculated that contributions in the amount of $719,000 were required for fiscal year 2011, and the Company does not expect anypaid these contributions to be paid to the plans during the remainder of the current fiscal year.in August 2010.

Pension expense (income) consisted of the following (in thousands):

 

   Three months ended
January 31, 2010
  Three months ended
January 31, 2009
 

Service Cost

  $-0-   $-0-  

Interest Cost

   238    224  

Expected return on plan assets

   (235  (338

Recognition of net loss

   174    40  
         

Net periodic pension expense (income)

  $177   $(74
         
   Nine months ended
January 31, 2010
  Nine months ended
January 31, 2009
 

Service Cost

  $-0-   $-0-  

Interest Cost

   713    672  

Expected return on plan assets

   (704  (1,014

Recognition of net loss

   521    120  
         

Net periodic pension expense (income)

  $530   $(222
         

   Three months ended
July 31, 2010
  Three months ended
July 31, 2009
 

Service cost

  $-0-   $-0-  

Interest cost

   240    230  

Expected return on plan assets

   (289  (235

Recognition of net loss

   172    160  
         

Net periodic pension expense

  $123   $155  
         

F.Credit Arrangement

In July 2009, the Company amended its unsecured revolving credit facility to extend the facility’s expiration date to July 31, 2012, and modify the variable rate component of the interest calculation. Monthly interest payments under the facility, as amended, are payable calculated at the 30-day LIBOR Market Interest Rate plus a variable rate ranging from 1.575% to 2.175%.

G.Derivative Instruments and Hedging Activities

Cash Flow Hedges – Interest Rate Swap Agreement

In July 2009,As described in Note G below, in June 2010, the Company entered into an interest rate SWAPswap agreement with a initial notional amount of $4 million, whereby the interest rate payable by the Company on $2 millionthe unpaid balance of outstanding advances under the revolving credit facility wasnew term loan is effectively converted to a fixed interest rate of 3.9%4.875% for the period beginning August 3, 2009,2, 2010, and ending August 1, 2012.

2017. The Company entered into this interest rate swap to mitigate future interest rate risk associated with advances under the credit facility. The Company does not use derivatives for trading or speculative purposes. The effective portion of changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income (loss) and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. The Company did not record any hedge ineffectiveness in earnings during the three months or nine months ended JanuaryJuly 31, 2010 and 2009. Amounts reported in accumulated other comprehensive loss related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s revolving credit facility.

The change in fair value of cash flow hedge,hedges, net of tax for the three and nine months ended JanuaryJuly 31, 2010 was $29,000.$11,000. The change in fair value was recorded in the Company’s consolidated balance sheet as a current liability and accumulated other comprehensive loss.

G.Subsequent Events

On August 2, 2010, the Company amended its existing bank agreement covering its unsecured $14 million revolving credit facility to provide for an additional $4 million seven-year term loan secured by the Company’s real property and equipment located in Statesville, North Carolina. The term loan requires monthly principal payments of approximately $17,000, plus interest calculated at the 30-day LIBOR Market Index Rate plus 1.575%, with payment of the outstanding principal balance and any unpaid interest at the term loan maturity date. In June 2010, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on the term loan was effectively converted to a fixed interest rate of 4.875%, effective August 2, 2010. The term loan includes financial covenants similar to the unsecured revolving credit facility. The proceeds of the term loan will be used primarily to fund the expansion of the Company’s Statesville, North Carolina manufacturing facilities.

H.Reclassifications

Certain 2009 amounts have been reclassified to conform with the 2010 presentation in the consolidated statements of cash flows. Such reclassifications had no impact on net earnings.

 

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Company’s 20092010 Annual Report to Stockholders contains management’s discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2009.2010. The following discussion and analysis describes material changes in the Company’s consolidated financial condition since April 30, 2009.2010. The analysis of results of operations compares the three and nine months ended JanuaryJuly 31, 2010 with the comparable periodsperiod of the prior fiscal year.

Results of Operations

Sales for the three months ended JanuaryJuly 31, 2010 were $21,814,000,$24,858,000, a decrease of 16%5% from sales of $26,023,000$26,249,000 in the same period last year. Sales from Domestic Operations were $19,081,000,$20,948,000, a decrease of 15% from the prior year period. Sales from Domestic Operations for the three month period were affected by a soft market for small laboratory furniture projects, and unusually bad weather which delayed the start of many construction projects. Sales from International Operations were $2,733,000, a decrease of 22% from the prior year period.

Sales for the nine months ended January 31, 2010 were $75,151,000, a decrease of 5% from sales of $79,150,000 in the same period last year. Sales from Domestic Operations were $67,152,000, relatively unchanged when compared to the prior year period. Sales from International Operations were $7,999,000, a decrease of 33%10% from the prior year period. The decline was primarily the result of on-going softness in the marketplace for small and mid-sized laboratory projects and the scheduled timing of shipments in the order backlog. Sales from International Operations sales for both the three and nine month periods resulted from lower demand resultingwere $3,910,000, an increase of 35% from the slowdown in Asia of construction activity. The order backlog at January 31, 2010 was $65.5 million,prior year period, as compared to a backlog of $65.2 million at October 31, 2009 and $60.7 million at January 31, 2009.the Company experienced increased international sales opportunities.

The gross profit margin for the three months ended JanuaryJuly 31, 2010 was 21.5%20.1% of sales, as compared to 19.0%22.0% of sales in the comparable quarter of the prior year. The gross profit margin for the nine months ended January 31, 2010 was 22.2% of sales, as compared to 20.6% of sales in the comparable quarter of the prior year. The increasesdecreases in the gross profit margin percentages were primarily due to increased manufacturing efficiencies, savings from alternative sources of raw materials and components, and other cost improvements.lower sales prices due to the competitive marketplace.

Operating expenses for the three months ended JanuaryJuly 31, 2010 were $3,663,000,$3,901,000, or 16.8%15.7% of sales, as compared to $3,440,000,$3,966,000, or 13.2% of sales, in the comparable period of the prior year. Operating expenses for the nine months ended January 31, 2010 were $11,605,000, or 15.4% of sales, as compared to $10,884,000, or 13.8%15.1% of sales, in the comparable period of the prior year. The increasedecrease in operating expenses for the current quarter was primarily due to an increase of $295,000 for costs associated with benefit plans, $208,000 for sales and marketing costs, and an increase of $32,000 in depreciationlower incentive compensation expense, partially offset by lowerhigher operating expenses of $205,000 related to accrued compensation for incentive bonus plans.at our foreign subsidiaries. The increase in operating expenses forexpense as a percent of sales was due to the nine months oflower sales level in the current year was primarily due to an increase of $234,000 in administrative salaries, an increase of $753,000 for costs associated with benefit plans, and an increase of $98,000 in depreciation expense, partially offset by lower expenses of $392,000 related to accrued compensation for incentive bonus plans.period.

Operating earnings were $1,022,000 and $5,054,000$1,098,000 for the three and nine months ended JanuaryJuly 31, 2010. This compares to operating earnings of $1,494,000 and $5,420,000$1,798,000 for the comparable periodsperiod of the prior year.

Interest expense was $35,000 and $115,000$45,000 for the three and nine months ended JanuaryJuly 31, 2010, respectively, as compared to $49,000 and $231,000$41,000 for the comparable periodsperiod of the prior year. The decrease in interest expenseincrease for the current year periodsperiod resulted from lower interest rates paid on advances under the Company’s bank credit facility.an increase in short-term borrowings.

There was no other income and other expense in the three and nine months ended January 31, 2010, as compared to other income of $3,000 and other expense of $36,000 for the three and nine months ended January 31, 2009, respectively.

Income tax expense of $333,000 and $1,673,000$329,000 was recorded for the three and nine months ended JanuaryJuly 31, 2010, respectively, as compared to income tax expense of $488,000 and $1,595,000$589,000 recorded for the comparable periodsperiod of the prior year. The effective tax rates were 33.7% and 33.9%rate was 31.2% for the three and nine months ended JanuaryJuly 31, 2010, respectively, and were 33.7% and 31.0%was 33.5% for the comparable periodsperiod of the prior year. The effective tax rates for each of the current year and prior year periodsperiod were below the statutory tax rates due to the combination of lower income tax rates in the geographic locations of the Company’s subsidiaries and the impact of state and federal income tax credits on domestic operations income. The higher effective tax rates for the current year period as compared to the prior year period was due to a higher portion of taxable earnings in the prior year period from the Company’s subsidiaries located in geographic locations with lower income tax rates.

MinorityNoncontrolling interests related to the Company’s two subsidiaries that are not 100% owned by the Company reduced net earnings by $33,000 and $222,000$67,000 for the three and nine months ended JanuaryJuly 31, 2010, as compared to a reduction of $78,000 and $231,000$97,000 for the comparable periodsperiod of the prior year. The decrease in minority interests in the current year periodsperiod was directly related to lower earnings of the Company’s two subsidiaries in the current year.

Net earnings were $621,000,$657,000, or $0.24 per diluted share, and $3,044,000, or $1.18$0.25 per diluted share, for the three and nine months ended JanuaryJuly 31, 2010. This compares to net earnings of $882,000,$1,071,000, or $0.35 per diluted share, and $3,327,000, or $1.30$0.42 per diluted share, for the comparable periodsperiod of the prior year.

Liquidity and Capital Resources

Historically, the Company’s principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company’s revolving credit facility. Additionally, certainCertain machinery and equipment are financed by non-cancellable operating leases or capital leases. Additionally, the current expansion of the Company’s Statesville, North Carolina manufacturing facilities is to be funded by a new $4 million term loan. See Note G of the Notes to the Consolidated Financial Statements included in Part 1, Item 1 of this Quarterly Report Form 10-Q for a description of the term loan agreement and related interest rate swap. The Company believes that these sources will be sufficient to support ongoing business requirements, including capital expenditures through the current fiscal year.

The Company had working capital of $21.3$18.9 million at JanuaryJuly 31, 2010, compared to $18.9$20.1 million at April 30, 2009.2010. The ratio of current assets to current liabilities was 2.6-to-1.01.9-to-1.0 at JanuaryJuly 31, 2010, compared to 2.0-to-1.02.1-to-1.0 at April 30, 2009.2010. At JanuaryJuly 31, 2010, advances of $2,909,000$7,496,000 were outstanding under the Company’s bank revolving credit facility, as compared to advances of $5,720,000$4,872,000 outstanding as of April 30, 2009.2010.

The Company’s operations providedused cash of $5,027,000$88,000 during the ninethree months ended JanuaryJuly 31, 2010. Cash was provided primarily from operating earnings and a decreaseoffset by an increase of $1,412,000$1,299,000 in accounts receivable. The Company’s operations provided cash of $340,000$1,246,000 during the ninethree months ended JanuaryJuly 31, 2009 as cash provided from operating earnings was substantiallyand a decrease of $616,000 in accounts receivable, which were partially offset by cash used to fund an increase of $4,800,000 in accounts receivable.inventory on hand.

During the ninethree months ended JanuaryJuly 31, 2010, net cash of $3,130,000$2,156,000 was used in investing activities, primarily for capital expenditures. This compares to the use of $1,074,000$2,022,000 for investing activities in the comparable period of the prior year, primarily for capital expenditures.

The Company’s financing activities usedprovided cash of $3,694,000$2,342,000 during the ninethree months ended JanuaryJuly 31, 2010. Cash usedprovided included $2,624,000 received from short-term borrowings, which was partially offset by cash dividends of $719,000$257,000 paid to stockholders,stockholders. Financing activities provided cash of $223,000 during the three months ended July 31, 2009. Cash provided included $509,000 received from short-term borrowings, which was partially offset by cash dividends paid of $205,000 and payments on obligations ofunder capital leases of $186,000, purchases of treasury stock of $245,000, and $2,811,000 for a reduction in short-term borrowings, partially offset by $267,000 in proceeds received from the exercise of stock options. The Company’s financing activities used cash of $27,000 during the nine months ended January 31, 2009. Cash used included cash dividends of $498,000 paid to minority interest holders of the Company’s subsidiaries, cash dividends of $613,000 paid to stockholders, payments on obligations of capital leases of $280,000, and purchases of treasury stock of $198,000. Cash was provided during this period by an increase of $1,264,000 in short-term borrowings and $298,000 in proceeds received from the exercise of stock options.$81,000.

Outlook for Fourth Quarter of Fiscal Year 20102011

While theThe Company’s ability to predict future demand for its products continues to be limited given, among other general economic factors affecting the Company and its markets, the Company’s role as subcontractor or supplier to dealers for subcontractors, and the Company expects the fourth quarter of fiscal year 2010 to be profitable. In addition to general economic factors affecting the Company and its markets,fact that demand for its products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction.

The Company expects that sales and earnings for the first half of fiscal year 2011 will likely be below the prior year period, followed by a stronger second half of the year. The Company’s expectations are based on a number of factors, including scheduled delivery dates for orders in the order backlog, a partial recovery of the global economy, continuing increased sales opportunities for the Company’s products in the international marketplace, sales and earnings benefits from new products, and increased manufacturing capabilities in the Company’s Statesville, North Carolina and Bangalore, India facilities.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements in this report constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company’s operations, markets, products, services, and prices, as well as prices for certain raw materials and energy. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms “believes”, “belief”, “expects”, “plans”, “objectives”, “anticipates”, “intends” or the like to be uncertain and forward-looking. Over time, the Company’s actual results, performance or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by the Company’s forward-looking statements, and such difference might be significant and harmful to stockholders’ interests. Many important factors that could cause such a difference are described under the caption “Risk Factors,” in Item 1A of the Company’s 20092010 Annual Report on Form 10-K.

REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

A review of the interim consolidated financial information included in this Quarterly Report on Form 10-Q for each of the three and nine month periods ended JanuaryJuly 31, 2010 and JanuaryJuly 31, 2009 has been performed by Cherry, Bekaert & Holland, L.L.P., the Company’s independent registered public accounting firm. Their report on the interim consolidated financial information follows.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have reviewed the accompanying consolidated balance sheet of Kewaunee Scientific Corporation and its subsidiaries (the “Company”) as of JanuaryJuly 31, 2010, and the related consolidated statements of operations for the three month and nine month periods ended JanuaryJuly 31, 2010 and 2009 and the related consolidated statements of cash flows for the nine-monththree-month periods ended JanuaryJuly 31, 2010 and 2009. These interim consolidated financial statements are the responsibility of the Company’s management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the interim consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of April 30, 20092010 and the related consolidated statements of operations, of stockholder’s equity and of cash flows for the year then ended (not presented herein) and in our report dated July 10, 2009,16, 2010, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of April 30, 20092010 is fairly stated in all material respects in relation to the consolidated financial statement from which it has been derived.

/s/ Cherry, Bekaert & Holland, L.L.P.
Charlotte, North Carolina
September 13, 2010

Charlotte, North Carolina

March 12, 2010

Item 3.Quantitative and Qualitative Disclosures About Market Risk

There are no material changes to the disclosures made on this matter in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2009.2010.

 

Item 4.Controls and Procedures

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of JanuaryJuly 31, 2010. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that, as of JanuaryJuly 31, 2010, the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There was no significant change in the Company’s internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

 

Item 6.Exhibits

 

10.1Kewaunee Scientific Corporation Fiscal Year 2011 Incentive Bonus Plan.*(1)
31.1  Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2  Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1  Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2  Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

*The referenced exhibit is a management contract or compensatory plan, or arrangement.
(1)Filed as an exhibit to the Kewaunee Scientific Corporation Current Report on Form 8-K (Commission File No. 0–5286) filed on June 28, 2010, and incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  

KEWAUNEE SCIENTIFIC CORPORATION

(Registrant)

Date: March 12,September 14, 2010  By 

/s/ D. Michael Parker

   D. Michael Parker
 

D. Michael Parker

(As duly authorized officer and Senior Vice President, Finance and Chief Financial Officer)

 

1312